FDA 483 - CDYMAX (INDIA) PHARMA PRIVATE LIMITED - February 28, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Cdymax (India) Pharma Private Limited, a drug manufacturer in Bangalore, India, was cited for deficiencies in laboratory records during an FDA inspection. The observations primarily concern incomplete data from tests, examinations, and assays, specifically regarding microbial enumeration test method suitability and inadequate isolate identification for both raw material monitoring and environmental monitoring in production areas. These issues indicate a lack of assurance in compliance with established specifications and standards.
ID · 86b3641b-018a-4026-8442-dd024e713f8b